tradingkey.logo

Zevra Therapeutics Inc <ZVRA.OQ> expected to post a loss of 19 cents a share - Earnings Preview

ReutersMay 9, 2025 9:28 PM
  • Zevra Therapeutics Inc ZVRA.OQ ZVRA.O is expected to show a rise in quarterly revenue when it reports results on May 13 for the period ending March 31 2025

  • The Celebration Florida-based company is expected to report a 395.1% increase in revenue to $16.958 million from $3.43 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Zevra Therapeutics Inc is for a loss of 19 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Zevra Therapeutics Inc is $22.00​, above​ its last closing price of $7.79. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.40

-0.40

-0.69

Missed

-70.7

Sep. 30 2024

-0.42

-0.42

-0.69

Missed

-63.8

Jun. 30 2024

-0.44

-0.43

-0.48

Missed

-10.6​

Mar. 31 2024

-0.48

-0.48

-0.40

Beat

16.3

​​Dec. 31 2023

-0.19

-0.27

-0.40

Missed

-49.1

Sep. 30 2023

-0.30

-0.30

-0.40

Missed

-34.5​

Jun. 30 2023

-0.37

-0.34

-0.15

Beat

56.3

Mar. 31 2023

-0.24

-0.23

-0.34

Missed

-46.2

This summary was machine generated May 9 at 21:28 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI